OncoTherapy Science, Inc. Logo

OncoTherapy Science, Inc.

Biopharmaceutical company researching and developing novel anti-cancer therapies.

4564 | T

Overview

Corporate Details

ISIN(s):
JP3202150003
LEI:
Country:
Japan
Address:
川崎市川崎区東田町1番地2

Description

OncoTherapy Science, Inc. is a biopharmaceutical company focused on the research and development of novel anti-cancer therapies. The company utilizes cancer-specific gene data and comprehensive cancer genome analysis to discover and develop molecular-targeted drugs, antibody drugs, cancer vaccines, and new immunotherapies. Its key technological focuses include liquid biopsy, neoantigen prediction, and T-cell receptor (TCR) repertoire analysis using next-generation sequencing. The company's primary objective is to develop highly effective cancer treatments with minimal adverse events and side effects for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-08-08 02:19
四半期報告書-第22期第1四半期(令和4年4月1日-令和4年6月30日)
Japanese 203.9 KB
2022-08-08 02:19
確認書
Japanese 8.2 KB
2022-06-21 08:51
内部統制報告書-第21期(令和3年4月1日-令和4年3月31日)
Japanese 23.0 KB
2022-06-21 08:47
確認書
Japanese 8.2 KB
2022-06-21 08:45
有価証券報告書-第21期(令和3年4月1日-令和4年3月31日)
Japanese 968.3 KB
2022-02-07 01:14
四半期報告書-第21期第3四半期(令和3年10月1日-令和3年12月31日)
Japanese 224.3 KB
2021-11-08 01:10
四半期報告書-第21期第2四半期(令和3年7月1日-令和3年9月30日)
Japanese 249.5 KB
2021-08-10 03:48
四半期報告書-第21期第1四半期(令和3年4月1日-令和3年6月30日)
Japanese 249.0 KB
2021-06-22 07:29
内部統制報告書-第20期(令和2年4月1日-令和3年3月31日)
Japanese 23.1 KB
2021-06-22 07:27
確認書
Japanese 8.2 KB
2021-06-22 07:26
有価証券報告書-第20期(令和2年4月1日-令和3年3月31日)
Japanese 1003.0 KB
2021-02-08 01:13
四半期報告書-第20期第3四半期(令和2年10月1日-令和2年12月31日)
Japanese 213.3 KB
2020-11-09 01:27
四半期報告書-第20期第2四半期(令和2年7月1日-令和2年9月30日)
Japanese 240.6 KB
2020-11-09 01:13
訂正有価証券報告書-第19期(平成31年4月1日-令和2年3月31日)
Japanese 597.9 KB
2020-08-11 02:58
四半期報告書-第20期第1四半期(令和2年4月1日-令和2年6月30日)
Japanese 210.0 KB

Automate Your Workflow. Get a real-time feed of all OncoTherapy Science, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OncoTherapy Science, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OncoTherapy Science, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.